MDWD vs. URGN

Last updated Jun 3, 2026

MDWD (MediWound Ltd.) and URGN (UroGen Pharma Ltd.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, MDWD returned -10.64%/yr vs 7.68%/yr for URGN. At a 0.16 correlation, their price movements are largely independent.

Performance

MDWD vs. URGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MediWound Ltd. (MDWD) and UroGen Pharma Ltd. (URGN). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MDWD achieves a -25.46% return, which is significantly lower than URGN's 13.32% return.

MDWD

• 1D: -0.43%
• 1M: -17.26%
• YTD: -25.46%
• 6M: -20.69%
• 1Y: -38.13%
• 3Y*: 15.59%
• 5Y*: -10.64%
• 10Y*: -12.99%

URGN

• 1D: -1.81%
• 1M: 15.39%
• YTD: 13.32%
• 6M: 8.86%
• 1Y: 448.35%
• 3Y*: 39.67%
• 5Y*: 7.68%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

MDWD vs. URGN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
MDWD MediWound Ltd.	-25.46%	3.71%	75.02%	-24.61%	-18.34%	-36.22%	19.35%	-23.65%	-8.76%	-26.75%
URGN UroGen Pharma Ltd.	13.32%	119.91%	-29.00%	69.11%	-6.73%	-47.23%	-46.00%	-22.50%	15.72%	166.17%

Correlation

The correlation between MDWD and URGN is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.21
Correlation (3Y) Calculated over the trailing 3-year period	0.17
Correlation (5Y) Calculated over the trailing 5-year period	0.17
Correlation (All Time) Calculated using the full available price history since May 5, 2017	0.16

Fundamentals

Market Cap MDWD : $177.15M URGN : $1.33B
EPS MDWD : -$2.20 URGN : -$2.73
PS Ratio MDWD : 11.30 URGN : 9.22
Total Revenue (TTM) MDWD : $14.48M URGN : $140.49M
Gross Profit (TTM) MDWD : $2.84M URGN : $126.24M
EBITDA (TTM) MDWD : -$24.21M URGN : -$117.04M

Return for Risk

MDWD vs. URGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MDWD

MDWD Risk / Return Rank: 5
MDWD Sharpe Ratio Rank: 6
MDWD Sortino Ratio Rank: 7
MDWD Omega Ratio Rank: 9
MDWD Calmar Ratio Rank: 2
MDWD Martin Ratio Rank: 1

URGN

URGN Risk / Return Rank: 97
URGN Sharpe Ratio Rank: 98
URGN Sortino Ratio Rank: 98
URGN Omega Ratio Rank: 95
URGN Calmar Ratio Rank: 98
URGN Martin Ratio Rank: 97

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MDWD vs. URGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for MediWound Ltd. (MDWD) and UroGen Pharma Ltd. (URGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MDWD	URGN	Difference
Sharpe ratio Return per unit of total volatility	-0.92	4.62	-5.54
Sortino ratio Return per unit of downside risk	-1.27	5.13	-6.40
Omega ratio Gain probability vs. loss probability	0.85	1.60	-0.75
Calmar ratio Return relative to maximum drawdown	-0.98	12.46	-13.44
Martin ratio Return relative to average drawdown	-1.86	25.96	-27.81
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MDWD vs. URGN - Sharpe Ratio Comparison

The current MDWD Sharpe Ratio is -0.92, which is lower than the URGN Sharpe Ratio of 4.62. The chart below compares the historical Sharpe Ratios of MDWD and URGN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	MDWD	URGN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.92	4.62	-5.54
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.18	0.08	-0.26
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.21	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.27	0.09	-0.36

Drawdowns

MDWD vs. URGN - Drawdown Comparison

The maximum MDWD drawdown since its inception was -94.35%, roughly equal to the maximum URGN drawdown of -93.98%. Use the drawdown chart below to compare losses from any high point for MDWD and URGN.

Drawdown Indicators

	MDWD	URGN	Difference
Max Drawdown Largest peak-to-trough decline	-94.35%	-93.98%	-0.37%
Max Drawdown (1Y) Largest decline over 1 year	-36.59%	-42.22%	+5.63%
Max Drawdown (3Y) Largest decline over 3 years	-38.13%	-82.64%	+44.51%
Max Drawdown (5Y) Largest decline over 5 years	-82.04%	-82.64%	+0.60%
Max Drawdown (10Y) Largest decline over 10 years	-87.76%	—	—
Current Drawdown Current decline from peak	-89.18%	-59.38%	-29.80%
Average Drawdown Average peak-to-trough decline	-75.87%	-61.55%	-14.32%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.12%	20.26%	-0.14%

Volatility

MDWD vs. URGN - Volatility Comparison

The current volatility for MediWound Ltd. (MDWD) is 17.54%, while UroGen Pharma Ltd. (URGN) has a volatility of 20.26%. This indicates that MDWD experiences smaller price fluctuations and is considered to be less risky than URGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MDWD	URGN	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.54%	20.26%	-2.72%
Volatility (6M) Calculated over the trailing 6-month period	31.20%	46.54%	-15.34%
Volatility (1Y) Calculated over the trailing 1-year period	41.74%	98.75%	-57.01%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	61.09%	91.53%	-30.44%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	60.82%	79.57%	-18.75%

Dividends

MDWD vs. URGN - Dividend Comparison

Neither MDWD nor URGN has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both MDWD and URGN in my portfolio?

MDWD and URGN have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MDWD or URGN?

URGN has higher volatility (20.26%) compared to MDWD (17.54%). In terms of maximum drawdown, MDWD dropped -94.35% vs URGN's -93.98%.

Which has better risk-adjusted returns?

URGN currently has the higher Sharpe Ratio (4.62 vs -0.92), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.